Dr Thomas Lynch
Dr. Thomas J. Lynch, Jr. is the Chairman and Chief Executive Officer of the Massachusetts General Physicians Organization, starting in September 2015. Over the last 6 years, he served as the Director of Yale Cancer Center and has been the Richard and Jonathan Sackler Professor of Internal Medicine, Yale Cancer Center, Yale School of Medicine from 2009 to 2015. He also served as the Physician-in-Chief of Smilow Cancer Hospital, Yale-New Haven from 2009 to 2015. Prior to 2009, he served as Professor of Medicine for Harvard Medical School and Chief of Hematology/Oncology at Massachusetts General Hospital. Dr. Lynch is a member of the Association for Cancer Research, the American Society of Clinical Oncology, and the International Association for the Study of Lung Cancer. He also serves as a Director on the boards of the Kenneth B. Schwartz Center for Compassionate Healthcare, the National Comprehensive Cancer Network and Bristol-Myers Squibb. Dr. Lynch is a member of the Scientific Advisory Board of Arvinas, Inc.
Tariq Enver is Director at the University College London Cancer Institute & Professor of Stem Cell Biology. He was elected as an EMBO Fellow in 2009 and elected to the 1000 Talents Programme in China.
His research career has been principally concerned with understanding the mechanisms by which tissue and developmental stage specific gene expression is achieved and regulated with early work focusing on the regulation of the ?-globin gene clusters.
His current work deploys post-genomic technologies and mathematical modelling approaches to gain further insight into how blood stem cells are configured in molecular terms, the nature of the pathways involved in their cell fate decisions, and how these may be used in the pursuit of stem cell therapy and how they are corrupted by chimaeric transcription factors associated with human leukaemia.
Daniel Hochhauser is Co-Director of the Cancer Research UK-UCL Centre, Kathleen Ferrier Professor and consultant medical oncologist at University College London.
He has a clinical interest in gastrointestinal oncology. Research areas are in the modulation of DNA interactive agents by novel therapies including inhibition of the epidermal growth factor receptor. Additionally, he has an interest in early phase clinical trials and is currently principal investigator for several novel agents.
After qualifying in medicine from Cambridge and the Royal Free Hospital and postgraduate medical training in London and Oxford, he completed research for a DPhil at the Institute of Molecular Medicine in Oxford. Subsequently he worked as a medical oncology fellow at Memorial Sloan Kettering Cancer Center, New York before appointment as consultant in 1996.